Clinical trials: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Condition Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Funder type Industry (pharma, biotech, devices)
Marginal Zone Lymphoma, Follicular Lymphoma
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with…
- Conditions
- Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03520920
- Testing
- Zanubrutinib, Rituximab
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
B-Cell Lymphoma, Follicular Lymphoma
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma.
- Conditions
- B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
- Trial name
- NCT00085696
- Testing
- VELCADE and rituximab
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoma, Non-Hodgkin
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.
- Trial name
- TRANSCEND FL (NCT04245839)
- Testing
- Fludarabine, Cyclophosphamide, JCAR017
- Where
- 49 sites in United States, Austria and 8 more
- Volunteers
- 276 people
- Sponsor
- Celgene